Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

DAIICHI SANKYO’s Phase II Radiotherapy Breakthrough: 57% Response and Breakthrough FDA Designation

DAIICHI SANKYO’s Phase II radiotherapy trial for a rare blood disorder shows 57% response, 28% complete response, and strong safety—paving the way for accelerated approval and new oncology drugs.

Dr. Michael Chen

11/09/2026, 11:28

5 minutes to read

How Bayer’s New FDA‑Approved Drug and Winterrape Alliance Boost Cancer, Cardiac Care and Green Fuel

Discover how Bayer’s new tyrosine‑kinase drug HYRNUO and its winterrapé bio‑fuel partnership accelerate cancer care and low‑carbon energy—boosting health, sustainability, and shareholder value.

Dr. Michael Chen

11/09/2026, 00:54

4 minutes to read

Johnson & Johnson Unveils 24 New Mental‑Health Abstracts, Boosting Pipeline Diversification

Johnson & Johnson unveils 24 new mental‑health abstracts, spotlighting GABA‑B modulators, IL‑6R antibodies, gene‑editing and digital tools to fast‑track breakthroughs and diversify its pipeline.

Dr. Michael Chen

10/09/2026, 20:41

3 minutes to read

Royalty Pharma Slides as LDL‑Targeting Trial Fails, Showcasing Royalty‑Asset Risks

Royalty‑based biotech stocks fall after a failed LDL‑inhibitor trial, showing how a single negative study can reshape royalty valuation and investor strategy.

Dr. Michael Chen

10/09/2026, 04:09

4 minutes to read

Novo Nordisk Cancels Two Obesity Trials, Yet 71% of Children Succeed With Semaglutide

Novo Nordisk cancels two phase‑III obesity trials, but a late‑stage pediatric study shows 71 % BMI loss with semaglutide—boosting its obesity‑drug prospects.

Dr. Michael Chen

09/09/2026, 19:47

3 minutes to read

KMYY Pharma Strengthens Leadership & Governance to Accelerate Oncology Pipeline

KMYY Pharmaceutical’s new board, led by a seasoned Chairman and legal rep, drives governance, scientific rigor, and rapid regulatory paths for its PI3K‑δ inhibitor and bispecific T‑cell engager.

Dr. Michael Chen

09/09/2026, 04:53

3 minutes to read

Fidelity European Trust Q2 2026: Dividend Rise, AI‑Focused Portfolio, & Share‑Buyback Success

Fidelity European Trust’s 2026 half‑year report shows a 3.2% dividend rise, 5.8% NAV growth, and strategic focus on AI‑driven pharma, energy, and tech for sustained shareholder value.

Dr. Michael Chen

09/09/2026, 04:22

4 minutes to read

Illumina’s S&P 500 Re‑Entry Boosts Market, Science, & Regulatory Momentum

Illumina’s S&P 500 re‑entry boosts index‑fund demand while its next‑gen sequencing tech and FDA‑cleared diagnostics reinforce precision‑medicine growth.

Dr. Michael Chen

09/09/2026, 00:51

5 minutes to read

How Sartorius AG’s Bioprocessing Tech Drives mRNA & Gene Therapy Growth

Explore how Sartorius AG’s bioprocessing and automation tools keep mRNA, gene‑therapy and cell‑based therapies moving from lab to market.

Dr. Michael Chen

08/09/2026, 14:55

5 minutes to read

Novo Nordisk’s Mixed Trial Results: Pediatric Obesity Wins vs. Cardio Setbacks

New data reveal Novo Nordisk’s semaglutide cuts child BMI by 12.5% and 40% lose obesity, while its IL‑6 cardiovascular trials falter—what this means for the future of obesity and heart disease therapies.

Dr. Michael Chen

08/09/2026, 10:14

3 minutes to read

Older articles